{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:30:17Z","timestamp":1789065017613,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Antineutrophil cytoplasmic antibody\u2013associated vasculitis (AAV) is a systemic necrotizing vasculitis that predominantly affects small vessels. Glucocorticoids are the standard therapeutic agents for AAV; however, their long-term use can cause damage. Avacopan is a small-molecule complement component 5a receptor antagonist that reduces vasculitis and can potentially be used as an alternative to glucocorticoids. However, its therapeutic efficacy remains unknown, and drug-induced liver injury (DILI) is a concern associated with its use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 74-year-old woman with a history of granulomatosis with polyangiitis was admitted to our hospital with a 1-week history of fatigue and anorexia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>She had started avacopan 3 months before hospitalization. Blood tests showed severe liver injury, and since other diseases were ruled out, she was diagnosed with DILI secondary to avacopan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Avacopan was discontinued, and glucocorticoid doses were increased and ursodeoxycholic acid was administered; however, the liver injury did not resolve. Therefore, mycophenolate mofetil (MMF) was started.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The liver injury was resolved after starting MMF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>MMF is effective in treating DILI caused by avacopan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042121","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:00:58Z","timestamp":1744664458000},"page":"e42121","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Drug-induced liver injury due to avacopan improved by mycophenolate mofetil: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6533-7472","authenticated-orcid":false,"given":"Ryo","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Komae-si, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Komae-si, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takane","sequence":"additional","affiliation":[{"name":"Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Komae-si, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The Jikei University School of Medicine, Daisan Hospital, Komae-si, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Komae-si, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250414","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides.","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R2-20250414","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/s10165-009-0239-0","article-title":"Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan.","volume":"20","author":"Suzuki","year":"2010","journal-title":"Mod Rheumatol"},{"key":"R3-20250414","doi-asserted-by":"crossref","first-page":"102397","DOI":"10.1016\/j.jaut.2019.102397","article-title":"Alveolar haemorrhage in ANCA-associated vasculitis: long-term outcome and mortality predictors.","volume":"108","author":"Quartuccio","year":"2020","journal-title":"J Autoimmun"},{"key":"R4-20250414","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R5-20250414","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial.","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"R6-20250414","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis.","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20250414","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/mrcr\/rxad019","article-title":"Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"7","author":"Kataoka","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"R8-20250414","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R9-20250414","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury \u2013 types and phenotypes.","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N Engl J Med"},{"key":"R10-20250414","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI.","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"R11-20250414","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10067-015-2882-5","article-title":"Liver involvement in ANCA-associated vasculitis.","volume":"35","author":"Willeke","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R12-20250414","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2169\/internalmedicine.54.3678","article-title":"Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis associated with primary biliary cirrhosis: a case report and literature review.","volume":"54","author":"Yamashita","year":"2015","journal-title":"Intern Med"},{"key":"R13-20250414","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/key227","article-title":"Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial.","volume":"58","author":"Yunyun","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20250414","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury.","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R15-20250414","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1586\/17474124.2016.1127756","article-title":"Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.","volume":"10","author":"Stine","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R16-20250414","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan.","volume":"63","author":"Kojima","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R17-20250414","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan.","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl_4","key":"R18-20250414","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow\u2010up.","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"R19-20250414","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune\u2010related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R20-20250414","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"R21-20250414","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2165\/00003495-199651020-00007","article-title":"Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.","volume":"51","author":"Fulton","year":"1996","journal-title":"Drugs"},{"key":"R22-20250414","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40264-021-01051-5","article-title":"Overview of causality assessment for drug-induced liver injury (DILI) in clinical trials.","volume":"44","author":"Hey-Hadavi","year":"2021","journal-title":"Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:01:01Z","timestamp":1744664461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":22,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042121","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}